This is the inaugural study from the SOA’s Mortality and Longevity Strategic Research Program, which builds on existing research examining the factors affecting models and mortality predictions, including the analysis of longevity trends. Key findings from the study include the financial burden of the opioid epidemic across the following areas of the economy between 2015 and 2018:

• Healthcare: Nearly one-third ($205 billion) of the estimated economic burden is attributable to excess healthcare spending for individuals with opioid use disorder (OUD), infants born with neonatal abstinence syndrome or neonatal opioid withdrawal syndrome (NAS/NOWS), and for other family members of those with diagnosed OUD.
• Premature Mortality: Mortality costs accounted for 40 percent ($253 billion) of the estimated economic impact, predominantly driven by lost lifetime earnings for those who died prematurely due to drug overdoses involving opioids.
• Criminal Justice Activities: Costs associated with criminal justice activities, including police protection and legal adjudication activities, lost property due to crime, and correctional facility expenditures, totaled $39 billion, roughly 6 percent of the total cost from 2015 to 2018.
• Child and Family Assistance and Education Programs: Costs associated with governmentfunded child and family assistance programs and education programs contributed another $39 billion over the four-year period.
• Lost Productivity: Finally, lost productivity costs comprised the remaining 15 percent of total costs from 2015 through 2018, totaling $96 billion. Lost productivity costs are associated with absenteeism, reduced labor force participation, incarceration for opioid-related crimes, and employer costs for disability and workers’ compensation benefits to employees with opioid use disorder.

In addition to historical analysis, the SOA also projected costs for the opioid epidemic in 2019 based on three scenarios reflecting how the crisis may develop moving forward. The SOA’s midpoint cost estimate for 2019 is $188 billion, with its low and high cost estimates ranging from $172 billion to $214 billion. The cost estimates reflect a potential range of outcomes for key assumptions such as the prevalence of opioid use disorder and the number of opioid overdose deaths in 2019, and are intended to represent a few potential scenarios rather than the minimum or maximum of possible outcomes.